Trailing-twelve-month (TTM) revenue is $873.76 Million with a year-over-year growth of (7.45%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $156,719,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $203,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $246,091,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-29 |
| Q2 FY2026Period ended 2026-06-30 | $267,949,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $873,759,000 |
Current P/S: $7,307,110,480 market capitalization ÷ $873,759,000 TTM revenue = 8.36x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:10:19.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $267.95M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:12:19.665Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Collaborative Agreement Revenue | N/A | N/A | $207M | $353M | $333M | N/A |
| Commercial | $365M | $342M |
$873.76M
$873.76 Million
(7.45%)
vs. $944.09M a year ago (TTM)
+4.91%
5 Year compound annual growth rate
1 Year
(7.45%)
3 Year
+11.48%
5 Year
+4.91%
10 Year
+17.38%
15 Year
+15.47%
20 Year
+18.09%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $944.00M | +$238.86M | +33.87% |
| 2024 | $705.14M | ($82.51M) | (10.48%) |
| 2023 | $787.65M | +$200.28M | +34.10% |
| 2022 | $587.37M | ($223.09M) | (27.53%) |
| 2021 | $810.46M | +$81.19M | +11.13% |
| 2020 |
TTM Growth
(7.45%)
3-Year CAGR
+11.48%
5-Year CAGR
+4.91%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T19:12:19.665Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $309M |
| $293M |
| N/A |
| Commercial Member | N/A | N/A | N/A | N/A | N/A | $436M |
|---|
| Eplontersen Joint Development Revenue | N/A | N/A | $77M | N/A | N/A | N/A |
|---|
| Licensing and Other Royalties | $8M | $19M | $31M | $33M | N/A | N/A |
|---|
| Other | N/A | N/A | N/A | N/A | $23M | N/A |
|---|
| Other Commercial | N/A | N/A | N/A | $68M | $57M | N/A |
|---|
| Product | $70M | N/A | $30M | $35M | $34M | $115M |
|---|
| Research and Development Revenue | N/A | N/A | $284M | $479M | $412M | N/A |
|---|
| Research and Development Revenue Under Collaborative Agreements | $365M | $468M | N/A | N/A | N/A | N/A |
|---|
| Royalty | N/A | N/A | N/A | N/A | N/A | $286M |
|---|
| Spinraza Royalties | $287M | $268M | $242M | N/A | N/A | N/A |
|---|
| SPINRAZA Royalties | N/A | N/A | N/A | $240M | $216M | N/A |
|---|
| TEGSEDI and WAYLIVRA | N/A | $56M | N/A | N/A | N/A | N/A |
|---|
| $729.26M |
| ($393.33M) |
| (35.04%) |
| 2019 | $1.12B | +$522.92M | +87.20% |
| 2018 | $599.67M | +$85.50M | +16.63% |
| 2017 | $514.18M | +$141.40M | +37.93% |
| 2016 | $372.78M | +$89.07M | +31.40% |
